Shattuck Labs, Inc. (NASDAQ: STTK) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $4.00 price target on the stock.
MediumReport
Shattuck Labs, Inc. (NASDAQ: STTK) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $4.00 price target on the stock.
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
MediumReport
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 [Yahoo! Finance]
MediumReport
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 [Yahoo! Finance]
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
MediumReport
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: